Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 05, 2024

Impact of Primary Tumor Sidedness and Sex on Prognosis and Anti-EGFR Antibody Efficacy in BRAF-Mutant Metastatic Colorectal Cancer

ESMO Open

 

Additional Info

ESMO Open
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
ESMO Open 2024 Aug 21;9(9)103677, AHS Alig, DP Modest, S Stintzing, K Heinrich, M Geissler, L Fischer von Weikersthal, T Decker, U Vehling-Kaiser, S Held, N Moosmann, A Stahler, A Tannapfel, C Giessen-Jung, A Jung, L Weiss, V Heinemann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading